137 related articles for article (PubMed ID: 27229533)
1. Big data and computational biology strategy for personalized prognosis.
Ow GS; Tang Z; Kuznetsov VA
Oncotarget; 2016 Jun; 7(26):40200-40220. PubMed ID: 27229533
[TBL] [Abstract][Full Text] [Related]
2. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
4. Big genomics and clinical data analytics strategies for precision cancer prognosis.
Ow GS; Kuznetsov VA
Sci Rep; 2016 Nov; 6():36493. PubMed ID: 27819294
[TBL] [Abstract][Full Text] [Related]
5. Distinct prognostic values of four-Notch-receptor mRNA expression in ovarian cancer.
Zhou X; Teng L; Wang M
Tumour Biol; 2016 May; 37(5):6979-85. PubMed ID: 26662955
[TBL] [Abstract][Full Text] [Related]
6. Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.
Chen P; Huhtinen K; Kaipio K; Mikkonen P; Aittomäki V; Lindell R; Hynninen J; Auranen A; Grénman S; Lehtonen R; Carpén O; Hautaniemi S
Cancer Res; 2015 Aug; 75(15):2987-98. PubMed ID: 26122843
[TBL] [Abstract][Full Text] [Related]
7. Mechanistically derived patient-level framework for precision medicine identifies a personalized immune prognostic signature in high-grade serous ovarian cancer.
Zhao H; Gu S; Bao S; Yan C; Zhang Z; Hou P; Zhou M; Sun J
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32436954
[TBL] [Abstract][Full Text] [Related]
8. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.
Yousef GM; Kyriakopoulou LG; Scorilas A; Fracchioli S; Ghiringhello B; Zarghooni M; Chang A; Diamandis M; Giardina G; Hartwick WJ; Richiardi G; Massobrio M; Diamandis EP; Katsaros D
Cancer Res; 2001 Nov; 61(21):7811-8. PubMed ID: 11691797
[TBL] [Abstract][Full Text] [Related]
9. Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival.
Lisowska KM; Olbryt M; Student S; Kujawa KA; Cortez AJ; Simek K; Dansonka-Mieszkowska A; Rzepecka IK; Tudrej P; Kupryjańczyk J
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1239-52. PubMed ID: 27028324
[TBL] [Abstract][Full Text] [Related]
10. Multiple signatures of a disease in potential biomarker space: Getting the signatures consensus and identification of novel biomarkers.
Ow GS; Kuznetsov VA
BMC Genomics; 2015; 16 Suppl 7(Suppl 7):S2. PubMed ID: 26100469
[TBL] [Abstract][Full Text] [Related]
11. PATIENT-SPECIFIC DATA FUSION FOR CANCER STRATIFICATION AND PERSONALISED TREATMENT.
Gligorijević V; Malod-Dognin N; Pržulj N
Pac Symp Biocomput; 2016; 21():321-32. PubMed ID: 26776197
[TBL] [Abstract][Full Text] [Related]
12. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
[TBL] [Abstract][Full Text] [Related]
13. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
Yoshihara K; Tsunoda T; Shigemizu D; Fujiwara H; Hatae M; Fujiwara H; Masuzaki H; Katabuchi H; Kawakami Y; Okamoto A; Nogawa T; Matsumura N; Udagawa Y; Saito T; Itamochi H; Takano M; Miyagi E; Sudo T; Ushijima K; Iwase H; Seki H; Terao Y; Enomoto T; Mikami M; Akazawa K; Tsuda H; Moriya T; Tajima A; Inoue I; Tanaka K;
Clin Cancer Res; 2012 Mar; 18(5):1374-85. PubMed ID: 22241791
[TBL] [Abstract][Full Text] [Related]
14. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
[TBL] [Abstract][Full Text] [Related]
15. PenDA, a rank-based method for personalized differential analysis: Application to lung cancer.
Richard M; Decamps C; Chuffart F; Brambilla E; Rousseaux S; Khochbin S; Jost D
PLoS Comput Biol; 2020 May; 16(5):e1007869. PubMed ID: 32392248
[TBL] [Abstract][Full Text] [Related]
16. Small RNAs and the competing endogenous RNA network in high grade serous ovarian cancer tumor spread.
Bachmayr-Heyda A; Auer K; Sukhbaatar N; Aust S; Deycmar S; Reiner AT; Polterauer S; Dekan S; Pils D
Oncotarget; 2016 Jun; 7(26):39640-39653. PubMed ID: 27172797
[TBL] [Abstract][Full Text] [Related]
17. Novel personalized pathway-based metabolomics models reveal key metabolic pathways for breast cancer diagnosis.
Huang S; Chong N; Lewis NE; Jia W; Xie G; Garmire LX
Genome Med; 2016 Mar; 8(1):34. PubMed ID: 27036109
[TBL] [Abstract][Full Text] [Related]
18. Integrative methods for analyzing big data in precision medicine.
Gligorijević V; Malod-Dognin N; Pržulj N
Proteomics; 2016 Mar; 16(5):741-58. PubMed ID: 26677817
[TBL] [Abstract][Full Text] [Related]
19. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
[TBL] [Abstract][Full Text] [Related]
20. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
